Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALBT Avalon GloboCare	$2.14 +2.4%	$2.51	$1.87 ▼ $11.66	$8.02M	-0.02	1.43 million shs	50,856 shs
DRMA Dermata Therapeutics	$5.48 +2.8%	$6.52	$5.09 ▼ $24.90	$3.74M	0.56	27,894 shs	13,065 shs
JAGX Jaguar Animal Health	$1.80 -1.1%	$2.41	$1.78 ▼ $35.25	$3.48M	0.43	98,372 shs	129,159 shs
NMTR 9 Meters Biopharma		$0.00	$0.07 ▼ $6.56	$1.04M	1.36	315,915 shs	N/A

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALBT Avalon GloboCare	+2.39%	-6.14%	-10.08%	-43.24%	-57.29%
DRMA Dermata Therapeutics	+2.81%	-8.36%	-23.30%	-26.24%	-71.75%
JAGX Jaguar Animal Health	-1.10%	-14.29%	-24.37%	-59.91%	-93.79%
NMTR 9 Meters Biopharma	0.00%	0.00%	-99.72%	-99.72%	-81.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALBT Avalon GloboCare	1.2924 of 5 stars	0.0	2.0	0.0	4.3	2.8	1.7	0.0
DRMA Dermata Therapeutics	2.7309 of 5 stars	3.5	5.0	0.0	0.0	1.1	0.8	0.6
JAGX Jaguar Animal Health	2.2358 of 5 stars	3.5	3.0	0.0	0.0	2.3	0.0	0.6
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALBT Avalon GloboCare	0.00	N/A	N/A	N/A
DRMA Dermata Therapeutics	3.00	Buy	$10.00	82.48% Upside
JAGX Jaguar Animal Health	3.00	Buy	$60.00	3,233.33% Upside
NMTR 9 Meters Biopharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NMTR, ALBT, DRMA, and JAGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/21/2025	DRMA Dermata Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $10.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALBT Avalon GloboCare	$1.33M	6.18	N/A	N/A	($5.07) per share	-0.42
DRMA Dermata Therapeutics	N/A	N/A	N/A	N/A	$8.24 per share	N/A
JAGX Jaguar Animal Health	$11.69M	0.29	N/A	N/A	$2.30 per share	0.78
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	$0.19 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALBT Avalon GloboCare	-$7.90M	-$19.96	N/A	∞	N/A	-1,451.94%	N/A	-75.12%	11/10/2025 (Estimated)
DRMA Dermata Therapeutics	-$12.29M	-$16.41	N/A	∞	N/A	N/A	-214.98%	-153.76%	N/A
JAGX Jaguar Animal Health	-$38.49M	N/A	0.00	N/A	N/A	-344.16%	-660.18%	-77.42%	N/A
NMTR 9 Meters Biopharma	-$43.77M	-$3.46	N/A	N/A	N/A	N/A	-584.97%	-159.45%	N/A

Latest NMTR, ALBT, DRMA, and JAGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ALBT Avalon GloboCare	N/A	-$2.02	N/A	-$6.22	N/A	$0.35 million
8/14/2025	Q2 2025	JAGX Jaguar Animal Health	-$7.13	-$10.26	-$3.13	-$10.26	$3.27 million	$2.98 million
8/13/2025	Q2 2025	DRMA Dermata Therapeutics	-$2.90	-$1.66	+$1.24	-$1.66	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALBT Avalon GloboCare	N/A	N/A	N/A	N/A	N/A
DRMA Dermata Therapeutics	N/A	N/A	N/A	N/A	N/A
JAGX Jaguar Animal Health	N/A	N/A	N/A	N/A	N/A
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALBT Avalon GloboCare	N/A	0.06	0.19
DRMA Dermata Therapeutics	N/A	6.47	6.47
JAGX Jaguar Animal Health	2.44	0.95	0.70
NMTR 9 Meters Biopharma	N/A	0.59	0.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALBT Avalon GloboCare	1.42%
DRMA Dermata Therapeutics	8.67%
JAGX Jaguar Animal Health	12.04%
NMTR 9 Meters Biopharma	22.34%

Insider Ownership

Company	Insider Ownership
ALBT Avalon GloboCare	37.30%
DRMA Dermata Therapeutics	18.50%
JAGX Jaguar Animal Health	4.55%
NMTR 9 Meters Biopharma	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALBT Avalon GloboCare	5	3.84 million	1.19 million	Not Optionable
DRMA Dermata Therapeutics	8	682,000	556,000	Not Optionable
JAGX Jaguar Animal Health	50	1.91 million	1.83 million	No Data
NMTR 9 Meters Biopharma	20	14.34 million	13.99 million	No Data

NMTR, ALBT, DRMA, and JAGX Headlines

Recent News About These Companies

What is a prepayment meter?

August 24, 2024 | uswitch.comU

After coeliac fail, 9 Meters plots phase 3 in short bowel syndrome

July 28, 2024 | pharmaphorum.comP

Energy firms likely to miss smart meter deadline, warns Which?

December 14, 2023 | bbc.comB

Deal reached to sell some assets of bankrupt Raleigh firm

November 8, 2023 | bizjournals.com

9 Meters Biopharma, Inc. (NMTRQ)

November 7, 2023 | finance.yahoo.com

TRACK AND FIELD/ Yamagata sets Japan record in 100-meter sprint with 9.95 seconds

October 28, 2023 | asahi.comA

9 Meters Biopharma Inc (NMTRQ)

October 17, 2023 | investing.com

Vintage Meters Reborn As Steam Punk Clock

October 10, 2023 | hackaday.comH

9 Meters Biopharma (OTC: NMTR.Q)

August 16, 2023 | fool.com

Insider Sale Alert: 9 Meters Biopharma Inc. [NMTR] – Is it Time to sell?

July 25, 2023 | knoxdaily.comK

9 Meters Biopharma Inc. [NASDAQ: NMTR] Sees Decrease in Stock Value

July 21, 2023 | knoxdaily.comK

Raleigh firm joins worrying trend of bankruptcies for drugmakers

July 18, 2023 | bizjournals.com

Drug developer 9 Meters Biopharma files for bankruptcy protection

July 18, 2023 | reuters.com

Why Are 9 Meters Biopharma Shares Nosediving Today?

July 18, 2023 | finance.yahoo.com

Examining the Potential Price Growth of 9 Meters Biopharma Inc. (NMTR)

July 18, 2023 | knoxdaily.comK

Temperato resigns as CEO of Raleigh drugmaker

May 30, 2023 | bizjournals.com

9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome

May 30, 2023 | finance.yahoo.com

9 Meters Biopharma (NASDAQ: NMTR)

May 27, 2023 | fool.com

NMTR - 9 Meters Biopharma, Inc.

May 25, 2023 | uk.finance.yahoo.com

Citigroup Maintains 9 Meters Biopharma (NMTR) Neutral Recommendation

May 19, 2023 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMTR, ALBT, DRMA, and JAGX Company Descriptions

Avalon GloboCare NASDAQ:ALBT

$2.14 +0.05 (+2.39%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.10 -0.04 (-1.64%)

As of 08/22/2025 07:54 PM Eastern

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.

Dermata Therapeutics NASDAQ:DRMA

$5.48 +0.15 (+2.81%)

Closing price 08/22/2025 03:55 PM Eastern

Extended Trading

$5.75 +0.27 (+4.93%)

As of 08/22/2025 07:12 PM Eastern

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Jaguar Animal Health NASDAQ:JAGX

$1.80 -0.02 (-1.10%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.84 +0.04 (+2.50%)

As of 08/22/2025 07:43 PM Eastern

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

9 Meters Biopharma NASDAQ:NMTR

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time